Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Private Adimab Breaks $1 Billion Valuation, Offers VCs Liquidity Through $100 Million Secondary

This article was originally published in Start Up

Executive Summary

A secondary offering by the privately held antibody discovery play has valued the company at more than a billion dollars and allowed its venture investors to cash in some or all of their positions. Meanwhile, Adimab continues to announce new partnerships including a monoclonal and bispecific antibody discovery pact with Sanofi.


Related Content

VC Roundup: Relay Raises $57m To Seek Drug Targets Among Proteins In Motion
Adimab Discovers Sustainable Profitability Through GSK, Biogen Deals
Investing A La Carte: Making Separate Bets on Discovery and Development to Boost Near-Term Returns


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts